Journals / Turkish Journal of Gastroenterology / 2009 / Cilt: 20 - Sayı: 3

Seçilmiş karaciğer hastalıklarında apoptoz

Apoptosis in selected liver diseases

Pages
171–179
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Today, rational-based strategies are being developed to either promote or suppress apoptotic cell death as a novel therapeutic option in the treatment of these liver diseases.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cell death by apoptosis usually occurs in a regulated, limited fashion.
📊
Key Findings & Data:In contrast, defective apoptosis and increased cell proliferation is associated with cancer.
💡
Conclusion & Impact:Today, rational-based strategies are being developed to either promote or suppress apoptotic cell death as a novel therapeutic option in the treatment of these liver diseases.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Karaciğer hastalıkları · Karaciğer · Hücre ölümü

Abstract

Cell death by apoptosis usually occurs in a regulated, limited fashion. Only selected target cells are deleted in the process of ontogeny, development and regeneration. In contrast, under pathophysiological conditions, apoptosis imposes as a massive, chaotic, non-selective event that may occur for periods or even up to decades. It is likely that apoptosis is the initial cellular response to injury and may thus initiate several, intertwined cellular and cytokine cascades that culminate in tissue injury, inflammation, fibrosis and finally, in cirrhosis. Obviously, this cascade of events is of particular importance in various types of acute and chronic liver diseases. In contrast, defective apoptosis and increased cell proliferation is associated with cancer. Indeed, tumor cells often show alterations in genes regulating the apoptosis machinery. This overview is focused on the role of apoptosis in select important liver diseases. Today, rational-based strategies are being developed to either promote or suppress apoptotic cell death as a novel therapeutic option in the treatment of these liver diseases.

Özet

Apoptozla ilişkili hücre ölümü genellikle düzenli ve sınırlı şekilde oluşur. Yalnızca seçilmiş hedef hücreler oluşum, gelişim ve çoğalma sürecinde yok edilir. Bununla birlikte patofizyolojik durumlarda, apoptoz kısa bir dönem ya da bir kaç on yılı kapsayacak kadar uzun sürebilen yaygın, karmaşık ve seçici olmayan durum olarak karşımıza çıkabilir. Apoptoz muhtemelen hasara cevap olarak gelişen başlangıçtaki hücresel cevaptır ve doku hasarı, inflamasyon, fibrosis ve sirozla sonuçlanan birkaç hücresel ve sitokin kaskadını başlatabilir. Buna karşın yetersiz apoptoz ve aşırı hücre çoğalması kanserle ilişkilidir. Gerçektende, tümör hücreleri sıklıkla apoptozu regüle eden genlerde değişiklikler gösterirler. Bu derleme apoptozisin bazı önemli karaciğer hastalıklarındaki rolüne odaklanmıştır. Son zamanlarda, bahsedilen karaciğer hastalıkları için yeni tedavi seçeneği olarak apoptotik hücre ölümünü artıran ya da azaltan akla yatkın stratejiler geliştirilmektedir.

🔖

Cite This Article

KILIÇARSLAN, A., KAHRAMAN, A., AKKIZ, H., YILDIZ, Ş. S. M., FINGAS, C. D., GERKEN, G., CANBAY, A. (2009). Seçilmiş karaciğer hastalıklarında apoptoz. Turkish Journal of Gastroenterology, Cilt: 20 - Sayı: 3, 171–179. https://ajindex.com/articles/409871

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (23)

  1. Kerr J. History of the events leading to the formulation of the apoptosis concept. Toxicology 2002; 181-182: 471-4
  2. Kerr J, Wyllie A, Currie A. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-57
  3. Patel T, Roberts L, Jones B, Gores G. Dysregulation of apoptosis as a mechanism of liver disease: an overview. Semin Liver Dis 1998; 18: 105-14
  4. Malhi H, Gores GJ. Cellular and molecular mechanisms of liver injury. Gastroenterology 2008; 134: 1641-54
  5. Malhi H, Gores GJ, Lemasters JJ. Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology 2006; 43: 31- 44
  6. Canbay A, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004; 39: 273-8
  7. Galle PR, Krammer PH. CD95-induced apoptosis in human liver disease. Semin Liver Dis 1998; 18: 141-51
  8. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349: 474-85
  9. Lee WM. Acute liver failure in the United States. Semin Liver Dis 2003; 23: 217-26
  10. Jaeschke H, Gores GJ, Cederbaum AI, et al. Mechanisms of hepatotoxicity. Toxicol Sci 2002; 65: 166-76
  11. Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut 2005; 54: 1024-33
  12. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-12
  13. Henson PM, Bratton DL, Fadok VA. The phosphatidylserine receptor: a crucial molecular switch? Nat Rev Mol Cell Biol 2001; 2: 627-33
  14. Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature 2000; 407: 784-8
  15. Thornberry NA. Caspases: key mediators of apoptosis. Chem Biol 1998; 5: R97-103
  16. Rust C, Gores GJ. Apoptosis and liver disease. Am J Med 2000; 108: 567-74
  17. Gores GJ, Kaufmann SH. Is TRAIL hepatotoxic? Hepatology 2001; 34: 3-6
  18. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-6
  19. Canbay A, Higuchi H, Bronk SF, et al. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 2002; 123: 1323-30
  20. Song E, Lee SK, Wang J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003; 9: 347-51
  21. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-50
  22. Iredale JP. Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis 2001; 21: 427-36
  23. Iredale JP, Benyon RC, Pickering J, et al. Mechanism